Three years of ibrutinib in CLL
In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median tim...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2015-04-16.
|
| Subjects: | |
| Online Access: | Get fulltext |